Sagimet's partner Ascletis reports positive Phase 3 open-label 52-week acne data for denifanstat

Sagimet Biosciences Inc.

240 subjects received oral denifanstat 50 mg once daily for up to 40 weeks; 52 weeks total for prior denifanstat patients.
Denifanstat well tolerated: dry eye syndrome (5.5%) and dry skin (5.2%) most common TEAEs; no denifanstat-related SAEs.
No AE-related discontinuations; only 1 grade 1 hair thinning resolved without dose change; no deaths.
All efficacy endpoints (IGA, lesion counts) showed improvements beyond those seen at 12 weeks in the prior Phase 3 trial.
Ascletis holds China rights; Sagimet retains ex-China rights for denifanstat (FASN inhibitor).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.